Skip to main content

Table 4 Classification of preventable adverse events that we propose to use in this study*

From: Protocol for evaluation of the cost-effectiveness of ePrescribing systems and candidate prototype for other related health information technologies

State

Proportion

Utility

Mean duration, L (years)

Cost, 2009 (€)

Comments

Example

Death

0.078

0

3

3,831

Duration here is expected mean survival without the event, as estimated as weighted average from Zegers et al. [29]

Vincristine administered by intrathecal route.

Permanent disability

0.047

To be determined

6

6,649

Costs exclude long-term care. No data on mean duration, but a given adverse event is more likely to be fatal in an older person, so mean survival assumed to be a little longer than life years lost in those who died.

Haemorrhagic stroke in patient prescribed warfarin and macrolide antibiotics.

Moderate disability

0.617

To be determined

0.2

5,973

Duration ≤6 months in 70% of cases (Baker et al. [30])

Pulmonary embolism in large patient given standard (inadequate) dose of heparin.

Minimal effect

0.257

To be determined

0.05

2,979

 

Transient urticarial rash in known allergic patient given penicillin.

  1. *Based on Hoonhout et al. [28]